1. Home
  2. BPMC vs LCID Comparison

BPMC vs LCID Comparison

Compare BPMC & LCID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BPMC
  • LCID
  • Stock Information
  • Founded
  • BPMC 2008
  • LCID 2007
  • Country
  • BPMC United States
  • LCID United States
  • Employees
  • BPMC N/A
  • LCID N/A
  • Industry
  • BPMC Biotechnology: Pharmaceutical Preparations
  • LCID Auto Manufacturing
  • Sector
  • BPMC Health Care
  • LCID Consumer Discretionary
  • Exchange
  • BPMC Nasdaq
  • LCID Nasdaq
  • Market Cap
  • BPMC 8.3B
  • LCID 6.9B
  • IPO Year
  • BPMC 2015
  • LCID N/A
  • Fundamental
  • Price
  • BPMC N/A
  • LCID $2.92
  • Analyst Decision
  • BPMC Buy
  • LCID Hold
  • Analyst Count
  • BPMC 18
  • LCID 9
  • Target Price
  • BPMC $128.87
  • LCID $3.00
  • AVG Volume (30 Days)
  • BPMC 4.3M
  • LCID 193.0M
  • Earning Date
  • BPMC 07-31-2025
  • LCID 08-05-2025
  • Dividend Yield
  • BPMC N/A
  • LCID N/A
  • EPS Growth
  • BPMC N/A
  • LCID N/A
  • EPS
  • BPMC N/A
  • LCID N/A
  • Revenue
  • BPMC $562,121,000.00
  • LCID $870,140,000.00
  • Revenue This Year
  • BPMC $44.46
  • LCID $75.04
  • Revenue Next Year
  • BPMC $32.78
  • LCID $97.81
  • P/E Ratio
  • BPMC N/A
  • LCID N/A
  • Revenue Growth
  • BPMC 99.19
  • LCID 40.67
  • 52 Week Low
  • BPMC $73.04
  • LCID $1.93
  • 52 Week High
  • BPMC $129.65
  • LCID $4.43
  • Technical
  • Relative Strength Index (RSI)
  • BPMC 3.63
  • LCID 61.76
  • Support Level
  • BPMC $129.20
  • LCID $2.75
  • Resistance Level
  • BPMC $129.65
  • LCID $3.31
  • Average True Range (ATR)
  • BPMC 0.18
  • LCID 0.22
  • MACD
  • BPMC -16.40
  • LCID 0.07
  • Stochastic Oscillator
  • BPMC 0.00
  • LCID 64.29

About BPMC Blueprint Medicines Corporation

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

About LCID Lucid Group Inc.

Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.

Share on Social Networks: